Upon concurrent binding to CEA on cancer cells and CD3 on T cells, MEDI-565 mediates T cell activation and the subsequent killing of CEA-expressing target cells in a perforin- and granzyme-dependent manner that is insensitive to concentrations up to 5 μg/mL of soluble CEA [16], [17], [18]. The gene discussed is CEACAM7; the disease is cancer.